Dextroamphetamine Saccharate and Amphetamine Capsules Recalled for Failed Impurities Specifications
Granules Pharmaceuticals Inc. is recalling 3,384 bottles of mixed-salt amphetamine extended-release capsules (5 mg) distributed nationwide due to failed impurities and degradation specifications.
What this means for you
Cosmetic or documentation issue. No expected health impact, but the manufacturer is correcting the affected products.
Our severity reasoning: This is an FDA Class III recall, which by definition is unlikely to cause adverse health consequences. No illnesses, injuries, or deaths are reported in the source text, and the hazard is a manufacturing specification failure rather than an acute safety threat.
Plain-English summary
Granules Pharmaceuticals Inc. is recalling Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate and Amphetamine Sulfate extended-release capsules, 5 mg (100-capsule bottles, NDC 70010-029-01 and related package NDCs) due to failed impurities and degradation specifications. The affected lot is GPC250158A with an expiration date of 06-22-2027.
The recalled product was distributed nationwide in the USA. Patients taking this medication should consult their healthcare provider or pharmacist to determine whether they received affected product and for guidance on obtaining an alternative supply.
The recalled product
- Product
- DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE MONOHYDRATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE (DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE MONOHYDRATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE)
- Brand
- DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE MONOHYDRATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE
- Manufacturer
- Granules Pharmaceuticals Inc.
- Affected units
- 3,384
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot#: GPC250158A
- Exp Date: 06-22-2027
UPCs (6)
- 0370010029019
- 0370010030015
- 0370010032019
- 0370010034013
- 0370010031012
- 0370010033016
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 5 recalled by Granules Pharmaceuticals Inc. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 5 products in this recall →Related recalls
Same brand · DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE MONOHYDRATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE
- HighAmphetamine extended-release capsules contain immediate-release pellets after label mix-up
FDA (Drugs) · 2026-07-08
- ModerateAmphetamine extended-release capsules 20 mg recalled over impurity and degradation results
FDA (Drugs) · 2025-10-01
- ModerateAmphetamine extended-release capsules 15 mg recalled after impurity testing failure
FDA (Drugs) · 2025-10-01
- ModerateAmphetamine extended-release capsules 30 mg recalled after failing impurity specifications
FDA (Drugs) · 2025-10-01
- ModerateAmphetamine extended-release capsules 10 mg recalled over failed degradation specifications
FDA (Drugs) · 2025-10-01
Same manufacturer · Granules Pharmaceuticals Inc.
See all →- HighTrazodone tablets recalled over the presence of foreign tablets
FDA (Drugs) · 2026-02-11
- Moderate
- HighColchicine Capsules Recalled Due to Failed Dissolution Specifications
FDA (Drugs) · 2025-01-15
Same hazard · impurity degradation
See all →- ModerateEsomeprazole Magnesium oral suspension recalled for failed impurity specifications
FDA (Drugs) · 2025-05-28
- HighDiltiazem Hydrochloride extended-release capsules recalled due to failed quality specifications
FDA (Drugs) · 2023-02-08
- ModerateXiidra ophthalmic solution recalled for failed impurity and degradation specifications
FDA (Drugs) · 2022-06-15
- ModerateXiidra Ophthalmic Solution Recalled for Failed Impurity and Degradation Specifications
FDA (Drugs) · 2022-06-15
- ModeratehydrALAZINE HCl Tablets 10 mg Recalled for Failed Impurity Specifications
FDA (Drugs) · 2022-03-23